Last10K.com

Aeolus Pharmaceuticals, Inc. (AOLS) SEC Filing 10-K Annual report for the fiscal year ending Monday, September 30, 2013

Aeolus Pharmaceuticals, Inc.

CIK: 1261734 Ticker: AOLS
Document and Entity Information (USD $)
12 Months Ended
Sep. 30, 2013
Dec. 17, 2013
Mar. 31, 2013
Document And Entity Information      
Entity Registrant Name AEOLUS PHARMACEUTICALS, INC.    
Entity Central Index Key 0001261734    
Document Type 10-K    
Document Period End Date Sep. 30, 2013    
Amendment Flag false    
Current Fiscal Year End Date --09-30    
Is Entity a Well-known Seasoned Issuer? No    
Is Entity a Voluntary Filer? No    
Is Entity's Reporting Status Current? Yes    
Entity Filer Category Smaller Reporting Company    
Entity Common Stock, Shares Outstanding   134,550,065  
Public Float     $ 6,994,038
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2013    

View differences made from one year to another to evaluate Aeolus Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeolus Pharmaceuticals, Inc..

Continue

Assess how Aeolus Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets (unaudited) (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
Consolidated Statements Of Stockholders Equity (deficit)
A. Organization, Business And Summary Of Significant Accounting Policies
A. Organization, Business And Summary Of Significant Accounting Policies (policies)
A. Organization, Business And Summary Of Significant Accounting Policies (tables)
B. Summary Of Significant Accounting Policies
B. Summary Of Significant Accounting Policies - Fair Value (details)
B. Summary Of Significant Accounting Policies - Net Income (loss) Per Common Share (details)
B. Summary Of Significant Accounting Policies - Warrant Fair Value (details 1)
C Liquidity (details Narrative)
C. Liquidity
D. Investments
D. Investments (details Narrative)
E. Commitments
F. Stockholder's Equity (tables)
F. Stockholders' Equity (deficit)
F. Stockholders' Equity - Warrant Activity (details 2)
F. Stockholders' Equity - Warrants (details)
F. Stockholders’ Equity - Preferred Stock Warrants (deficit) (details 1)
G. Stock-based Compensation
G. Stock-based Compensation (details 3)
G. Stock-based Compensation (details 4)
G. Stock-based Compensation (details Narrative)
G. Stock-based Compensation (tables)
G. Stock-based Compensation - Details Of Stock Options (details 2)
G. Stock-based Compensation - Nonvested Options (details 1)
G. Stock-based Compensation - Stock Option Activity (details)
H. Income Taxes
H. Income Taxes (details 1)
H. Income Taxes (details 2)
H. Income Taxes (details)
H. Income Taxes (tables)
I. Agreements
J. Quarterly Financial Data (details)
J. Quarterly Financial Data (unaudited)
J. Quarterly Financial Data (unaudited) (tables)
Ticker: AOLS
CIK: 1261734
Form Type: 10-K Annual Report
Accession Number: 0001102624-13-001543
Submitted to the SEC: Fri Dec 20 2013 5:30:12 PM EST
Accepted by the SEC: Fri Dec 20 2013
Period: Monday, September 30, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aols/0001102624-13-001543.htm